Cynosure, Inc.(Nasdaq: CYNO), a leading developer and manufacturer of lasers and pulsed light sources, today announced that it has received pre-market approval from the Korea Food and Drug Administration for its two-in-one laser hair removal system, the Apogee Elite(TM). Cynosure expects to serve the Korean market through Seoul-based distributor OrientMG. Cynosure believes that the potential market opportunity in Korea may exceed 40 million consumers.
“In the two years since its U.S. FDA clearance, Cynosure’s Apogee Elite has become a leader in the laser hair removal market because of its ability to treat not only unwanted hair on all skin types, but also provide an array of cosmetic treatments,” said Michael R. Davin, Chairman and CEO of Cynosure.
“With this new ability to bring the Elite’s unique capabilities to physicians and aesthetic centers in South Korea, one of the largest Asian markets for
medical devices, Cynosure has expanded its growth potential.”
The Apogee Elite contains two laser systems — a 755nm Alexandrite laser and a high-powered 1064nm Nd:YAG laser — in one convenient unit, providing the optimal wavelengths for most laser cosmetic treatments. The 755nm wavelength can treat skin types I-IV and veins, while the 1064nm treats skin types V-VI and epidermal pigmented lesions.
The Apogee Elite’s combination of Alexandrite and Nd:YAG lasers within one system makes it particularly well suited for laser hair removal on all skin types, including tanned individuals. The Elite is a multi-application system that can also be utilized to provide treatments such as Cynosure’s popular LaserFACIAL(SM) for sun-damaged skin, as well as removal of leg and facial veins, and age spots.
“Prior to the Apogee Elite, two or three different lasers were required to treat the various skin types that we see in the Korean market,” said Douglas Kim, President of OrientMG. “Now, there is no need to choose which laser is more useful since the Elite is just as effective and easier to use than multiple systems.”
About OrientMG
OrientMG, located in Seoul, Korea, is the exclusive Korean distributor of Cynosure, Inc. A full-service medical device supplier to the dermatology, plastic surgery, primary care and dentistry markets, OrientMG has an extensive network of product and service representatives throughout South Korea.
For more information, contact OrientMG at +82 2 546 7577, or log onto http://www.orientmg.com.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are
used by physicians and other practitioners to perform non-invasive procedures
to remove hair, treat vascular lesions, rejuvenate skin through the treatment
of shallow vascular and pigmented lesions and temporarily reduce the
appearance of cellulite. Cynosure’s products include a broad range of laser
and other light-based energy sources, including Alexandrite, pulse-dye, Nd:YAG
and diode lasers, as well as intense pulsed light. Cynosure was founded in
1991.
For corporate or product information, contact Cynosure at 800-886-2966, or
visit http://www.cynosurelaser.com.
Any statements in this press release about future expectations, plans and
prospects for Cynosure, Inc., including statements about the markets in which
Cynosure’s products are sold, and other statements containing the words
“believes,” “anticipates,” “plans,” “expects,” “will,” and similar
expressions, constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including our history of operating losses, our
reliance on sole source suppliers, competition in the aesthetic laser
industry, economic, market, technological and other factors discussed in our
Registration Statement on Form S-1, as amended, filed with the SEC. In
addition, the forward-looking statements included in this press release
represent the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will cause the
Company’s views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this press release.
Contact: Timothy W. Baker
800-886-2966
tbaker@cynosurelaser.com
SOURCE Cynosure, Inc.
Web Site: http://www.cynosurelaser.com http://www.orientmg.com